The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy
Abstract
Hepatitis C virus (HCV)–related liver fibrosis progression is accelerated in human immunodeficiency virus (HIV)–infected patients. The effect of protease inhibitor (PI) therapy on liver fibrosis is unknown. The aim of this work was to analyze the impact of PI therapy on HCV–related liver fibrosis in HIV/HCV coinfected patients. We evaluated in a long–term follow–up retrospective cohort study the influence of antiretroviral therapy containing PI on liver fibrosis in 182 consecutive HIV/HCV coinfected patients. At liver biopsy, 63 patients had received PI and 119 patients had never been treated with PI. Relationships between liver histologic features, age, alcohol consumption, CD4 cell count, HIV–RNA load, and antiretroviral regimens were analyzed. Liver fibrosis stage was lower in patients receiving PIs by comparison with patients who had never received PIs (P = .03). The 5–, 15–, and 25–year cirrhosis rates were 2% versus 5%, 5% versus 18%, and 9% versus 27%, respectively, in patients who had received PIs compared with PI–untreated patients (P = .0006). Multivariate analysis identified 4 independent predictors of progression to cirrhosis: absence of protease inhibitor therapy (relative risk [RR] = 4.74, 95% confidence interval [CI], 1.34–16.67), heavy alcohol consumption (≥ 50 g daily) (RR = 4.71, 95% CI, 1.92–11.57), low CD4 cell count (<200/μL) (RR = 2.74, 95% CI, 1.17–6.41), and age at HCV contamination (≥20 years) (RR = 2.37, 95% CI, 1.04–5.38). In conclusion, protease inhibitor therapy might not accelerate progression to HCV–related cirrhosis. Furthermore, chronic use of antiretroviral therapy containing PI together with reduction of alcohol consumption and maintenance of high CD4 count could have a beneficial impact on liver fibrosis progression in HIV/HCV coinfected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Self-citationNatural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Self-citationThe Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Self-citationSoto, B., Sánchez-Quijano, A., Rodrigo, L., Olmo, J. A. D., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M. A., Rodríguez, M., Sales Gilabert, M., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80001-3 · Cited by 701
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., & Preston, F. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05413-5 · Cited by 497
John, M., Flexman, J., & French, M. A. H. (1998) · AIDS · doi:10.1097/00002030-199817000-00010 · Cited by 251
Bachem, M. G., Meyer, D., Melchior, R., Sell, K. M., & Gressner, A. M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115561 · Cited by 232
Lonergan, J. T., Behling, C., Pfander, H., Hassanein, T. I., & Mathews, W. C. (2000) · Clinical Infectious Diseases · doi:10.1086/313912 · Cited by 208
Cited by
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Self-citationRadaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610
Metadata
- Authors
- Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., & Poynard, T.
- Venue
- Hepatology
- Published
- 2001-08
- Volume
- 34
- Issue
- 2
- Pages
- 283-287
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2074424133
- Cited by
- 424
- References
- 15
- FWCI
- 23.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy. https://app.cochat.ai/papers/10.1053/jhep.2001.26517
- The paper
- Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., Katlama, C., & Poynard, T. (2001). Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy. Hepatology. https://doi.org/10.1053/jhep.2001.26517
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.